Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors
Cardioncology has emerged as a new field at the intersection of cardiology and oncology. Despite the fact that improving efficiency of antitumor treatment increased the survival of oncological hematological patients, the long-term cardiovascular consequences of this treatment have become more clinic...
Main Authors: | L. M. Kogoniya, M. O. Rusanov, V. E. Shikina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2022-07-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/567 |
Similar Items
-
Evaluation of subclinical cardiotoxicity in patients with breast cancer and arterial hypertension in two regimens of anthracycline-containing chemotherapy
by: A A Avalyan, et al.
Published: (2018-12-01) -
Cardiac computed tomography‐derived myocardial tissue characterization after anthracycline treatment
by: Koichi Egashira, et al.
Published: (2022-06-01) -
Inequity in care delivery in cardio-oncology: dissecting disparities in underrepresented populations
by: Shruti Rajesh Patel, et al.
Published: (2023-06-01) -
Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies
by: Anastasia Stella Perpinia, et al.
Published: (2022-08-01) -
Cardiooncology. Basic principles of prevention and treatment of cardiotoxicity in cancer patients
by: Ekaterina V. Plokhova, et al.
Published: (2019-04-01)